Q: What need is Immunomic Therapeutics, Inc. addressing? A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory....
Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine? A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of...
Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve? A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health...
Q: What need is Ayasdi addressing? A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management....
Q: What need is Siolta Therapeutics addressing? A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide....
VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report....
Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically? A: Survival rates are greater than 90% for cancers that are detected at an early stage....
Q: What need is Q² Solutions | EA Genomics addressing? A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease...
Q: What need is GeneDx addressing? A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases....
Q: What need is RTI International addressing? A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development....
